Purevax RCPCh FeLV

Authorised

This medicine is authorised for use in the European Union

vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia, feline leukeamia and feline Chlamydophila infections

Overview

Up-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website

Purevax RCPCh FeLV : EPAR - Medicine overview

Product information

Purevax RCPCh FeLV : EPAR - Product Information

Purevax RCPCh FeLV : EPAR - All Authorised presentations

Product details

• Name of medicine:
  Purevax RCPCh FeLV
• Active substance:
  • attenuated feline rhinotracheitis herpesvirus (FHV F2 strain)
  • inactivated feline calicivirosis antigens (FCV 431 and G1 strains)
  • attenuated feline panleucopenia virus (PLI IV)
  • FeLV recombinant canarypox virus (vCP97)
  • attenuated Chlamydophila felis (905 strain)
• International non-proprietary name (INN) or common name:
  vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia, feline leukeamia and feline Chlamydophila infections

Pharmacotherapeutic group

Immunologicals for felidae

Authorisation details

• EMA product number:
  EMEA/V/C/000085

Assessment history

Changes since initial authorisation of medicine

Purevax RCPCh FeLV : EPAR - Procedural steps taken and scientific information after authorisation

Initial marketing authorisation documents

Purevax RCPCh FeLV : EPAR - Scientific Discussion